Pulmonary Arterial Hypertension - 30/06/18
Résumé |
This article provides an overview of pulmonary arterial hypertension (PAH), beginning with the initial pathologic recognition of pulmonary hypertension more than 100 years ago and progressing to the current diagnostic categorization of PAH. It reviews the epidemiology, pathophysiology, genetics, and modern treatment of PAH. The article discusses several important recent studies that have highlighted the importance of new management strategies, including serial risk assessment and combination pharmacotherapy.
Le texte complet de cet article est disponible en PDF.Keywords : Pulmonary hypertension, Pulmonary arterial hypertension, BMPR2, REVEAL Registry, Phosphodiesterase-5 inhibitors, Endothelin receptor antagonists, Prostacyclin
Plan
| Disclosure: No relevant disclosures (M.W. Dodson, L.M. Brown). Steering Committee iNO (Bellerophon), Steering Committee CTEPH Registry (Bayer), Steering Committee United States Pulmonary Hypertension Scientific Registry (Actelion) (C.G. Elliott). |
Vol 14 - N° 3
P. 255-269 - juillet 2018 Retour au numéro
Article précédent
- The Right Heart-Pulmonary Circulation Unit in Systemic Hypertension
- Olga Vriz, Yoshiki Motoji, Francesco Ferrara, Eduardo Bossone, Robert Naeije
- Pulmonary Circulation on the Crossroads Between the Left and Right Heart in Systemic Sclerosis : A Clinical Challenge for Cardiologists and Rheumatologists
- Luna Gargani, Damien Voilliot, Michele D’Alto, Gergely Agoston, Antonella Moreo, Walter Serra, Francesco Pieri, Fabio Mori, Karina Wierzbowska-Drabik, Marco Matucci-Cerinic, Alberto Moggi-Pignone
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?